The Marie Curie Award, the most prestigious price by the European Association of Nuclear Medicine, has been awarded in 2018 for the project "Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer", lead by Christina Müller in collaboration with Nick van der Meulen (LRC/NES) EANM-Website(link is external). The team lead by Cristina Müller demonstrated that 161Terbium is a potentially highly effective therapeutic alternative to 177Lu-PSMA-617. Prostate-specific membrane antigen (PSMA), a membrane zinc metalloenzyme, emerged in the last yeards as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). PSMA-617 is a small molecule targeting PSMA with high affinity and can be labeled with various radionuclides for diagnostic and therapeutic purposes. Cristina Müller and co-workers demonstrated that 161Tb-PSMA-617 has an improved absorbed dose profile compared to 177Lu-PSMA-617.